Citadel Advisors’s Moderna MRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $212M | Sell |
3,026,200
-575,800
| -16% | -$29.8M | 0.02% | 535 |
|
|
2026
Q1 | $183M | Sell |
3,602,000
-3,294,500
| -48% | -$154M | 0.03% | 491 |
|
|
2025
Q4 | $203M | Buy |
6,896,500
+463,600
| +7% | +$12.6M | 0.03% | 481 |
|
|
2025
Q3 | $166M | Buy |
6,432,900
+1,734,700
| +37% | +$48.4M | 0.03% | 560 |
|
|
2025
Q2 | $130M | Buy |
4,698,200
+766,800
| +20% | +$20.2M | 0.02% | 601 |
|
|
2025
Q1 | $111M | Buy |
3,931,400
+503,800
| +15% | +$17.9M | 0.02% | 632 |
|
|
2024
Q4 | $143M | Buy |
3,427,600
+1,276,300
| +59% | +$61M | 0.02% | 547 |
|
|
2024
Q3 | $144M | Buy |
2,151,300
+363,300
| +20% | +$33.4M | 0.03% | 502 |
|
|
2024
Q2 | $212M | Sell |
1,788,000
-26,800
| -1% | -$3.39M | 0.04% | 327 |
|
|
2024
Q1 | $193M | Sell |
1,814,800
-199,100
| -10% | -$20.1M | 0.04% | 388 |
|
|
2023
Q4 | $200M | Sell |
2,013,900
-777,600
| -28% | -$65.4M | 0.04% | 344 |
|
|
2023
Q3 | $288M | Buy |
2,791,500
+1,083,200
| +63% | +$121M | 0.06% | 205 |
|
|
2023
Q2 | $208M | Sell |
1,708,300
-701,800
| -29% | -$93.6M | 0.04% | 308 |
|
|
2023
Q1 | $370M | Sell |
2,410,100
-559,000
| -19% | -$92.2M | 0.08% | 146 |
|
|
2022
Q4 | $533M | Buy |
2,969,100
+550,600
| +23% | +$90M | 0.12% | 94 |
|
|
2022
Q3 | $286M | Buy |
2,418,500
+49,600
| +2% | +$7.53M | 0.07% | 201 |
|
|
2022
Q2 | $338M | Sell |
2,368,900
-1,349,600
| -36% | -$193M | 0.09% | 149 |
|
|
2022
Q1 | $641M | Sell |
3,718,500
-42,200
| -1% | -$7.1M | 0.13% | 75 |
|
|
2021
Q4 | $955M | Buy |
3,760,700
+841,900
| +29% | +$246M | 0.2% | 48 |
|
|
2021
Q3 | $1.12B | Buy |
2,918,800
+1,389,800
| +91% | +$513M | 0.23% | 41 |
|
|
2021
Q2 | $359M | Sell |
1,529,000
-1,037,800
| -40% | -$185M | 0.08% | 145 |
|
|
2021
Q1 | $336M | Buy |
2,566,800
+904,700
| +54% | +$131M | 0.08% | 154 |
|
|
2020
Q4 | $174M | Buy |
1,662,100
+4,700
| +0.3% | +$475K | 0.05% | 313 |
|
|
2020
Q3 | $117M | Buy |
1,657,400
+754,300
| +84% | +$52.6M | 0.03% | 381 |
|
|
2020
Q2 | $58M | Buy |
903,100
+363,200
| +67% | +$19.9M | 0.02% | 710 |
|
|
2020
Q1 | $16.2M | Buy |
539,900
+493,800
| +1,071% | +$11.4M | 0.01% | 1409 |
|
|
2019
Q4 | $902K | Buy |
46,100
+10,800
| +31% | +$192K | ﹤0.01% | 5790 |
|
|
2019
Q3 | $562K | Sell |
35,300
-18,200
| -34% | -$269K | ﹤0.01% | 6552 |
|
|
2019
Q2 | $783K | Buy |
53,500
+32,100
| +150% | +$689K | ﹤0.01% | 6101 |
|
|
2019
Q1 | $435K | Buy |
+21,400
| New | +$397K | ﹤0.01% | 7021 |
|
Other funds holding MRNA
TP
Citadel Advisors's MRNA Position: Q2 2026 in Review
Citadel Advisors reduced its Moderna (MRNA) stake by 40% in Q2 2026, selling an estimated $10.1M and leaving 294,496 shares worth $20.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2542.
Citadel Advisors first reported a position in MRNA in Q1 2019 and has held it in 30 quarters since. The position peaked at $168M in Q2 2021. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.
- Citadel Advisors held 294,496 shares of Moderna worth $20.6M as of Q2 2026.
- Citadel Advisors sold 195,274 Moderna shares in Q2 2026, an estimated $10.1M.
- Moderna made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #2542 holding.
- Citadel Advisors first reported a position in Moderna in Q1 2019 and has held it in 30 quarters since.
- Citadel Advisors's Moderna position peaked at $168M in Q2 2021.
- 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.
Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.